Ferriprox(deferiprone)
Deferiprone, Ferriprox (deferiprone) is a small molecule pharmaceutical. Deferiprone was first approved as Ferriprox on 1999-08-25. It is used to treat iron overload in the USA. It has been approved in Europe to treat beta-thalassemia and iron overload.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Deferiprone, Ferriprox (discontinued: Ferriprox)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Deferiprone
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| FERRIPROX | Chiesi Farmaceutici | N-021825 RX | 2011-10-14 | 2 products, RLD |
| FERRIPROX | Chiesi Farmaceutici | N-208030 RX | 2015-09-09 | 1 products, RLD, RS |
| FERRIPROX | Chiesi Farmaceutici | N-212269 RX | 2020-05-19 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| OTC monograph not final | 2012-12-06 | |
| artistry exact fit longwearing foundation shade buff | C200263 | 2023-10-21 |
| artistry exact fit longwearing foundation shade chablis | C200263 | 2023-10-21 |
| artistry exact fit longwearing foundation shade cream | C200263 | 2023-10-21 |
| artistry hydra v sheer weightless foundation shade buff | C200263 | 2023-10-22 |
| artistry hydra v sheer weightless foundation shade chablis | C200263 | 2023-10-22 |
| artistry youth xtend lifting smoothing foundation shade buff | C200263 | 2023-10-22 |
| artistry youth xtend lifting smoothing foundation shade chablis | C200263 | 2023-10-22 |
| artistry youth xtend lifting smoothing foundation shade cream | C200263 | 2023-10-22 |
| deferiprone | ANDA | 2024-05-07 |
Show 3 more
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| iron overload | — | D019190 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
DEFERIPRONE, FERRIPROX, CHIESI | |||
| 2028-04-30 | ODE-417, ODE-418, ODE-419, ODE-420, ODE-421 | ||
| 2024-04-30 | I-859 | ||
HCPCS
No data
Clinical
Clinical Trials
2327 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | 153 | 252 | 121 | 3 | 69 | 520 |
| Lung neoplasms | D008175 | — | C34.90 | 109 | 200 | 105 | 1 | 55 | 415 |
| Neoplasms | D009369 | — | C80 | 262 | 170 | 10 | 3 | 36 | 376 |
| Carcinoma | D002277 | — | C80.0 | 99 | 203 | 62 | 3 | 44 | 356 |
| Melanoma | D008545 | — | — | 83 | 80 | 9 | 2 | 17 | 150 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 44 | 74 | 18 | 1 | 12 | 123 |
| Squamous cell carcinoma | D002294 | — | — | 31 | 74 | 21 | 1 | 14 | 119 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 34 | 48 | 11 | 2 | 28 | 108 |
| Uterine cervical neoplasms | D002583 | — | — | 23 | 34 | 15 | 4 | 12 | 77 |
| Papillomavirus infections | D030361 | — | — | 4 | 13 | 37 | 3 | 6 | 62 |
Show 52 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 58 | 73 | 24 | — | 16 | 146 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 29 | 41 | 12 | — | 29 | 100 |
| Triple negative breast neoplasms | D064726 | — | — | 37 | 46 | 17 | — | 4 | 90 |
| Colorectal neoplasms | D015179 | — | — | 42 | 44 | 6 | — | 7 | 84 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 38 | 43 | 13 | — | 5 | 80 |
| Lymphoma | D008223 | — | C85.9 | 39 | 43 | 6 | — | 3 | 76 |
| Adenocarcinoma | D000230 | — | — | 20 | 47 | 16 | — | 6 | 74 |
| Small cell lung carcinoma | D055752 | — | — | 23 | 37 | 10 | — | 9 | 71 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 22 | 39 | 12 | — | 14 | 68 |
| Head and neck neoplasms | D006258 | — | — | 31 | 36 | 8 | — | 4 | 60 |
Show 103 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sarcoma | D012509 | — | — | 14 | 20 | — | — | 1 | 28 |
| Wounds and injuries | D014947 | — | T14.8 | — | 1 | — | — | 16 | 17 |
| Skin neoplasms | D012878 | EFO_0004198 | C44 | 10 | 9 | — | — | — | 16 |
| Rectal neoplasms | D012004 | — | — | 3 | 11 | — | — | 2 | 14 |
| Cutaneous malignant melanoma | D000096142 | — | — | 8 | 10 | — | — | — | 14 |
| Syndrome | D013577 | — | — | 4 | 7 | — | — | 3 | 14 |
| Healthy volunteers/patients | — | — | — | 9 | 1 | — | — | 5 | 14 |
| Pancreatic ductal carcinoma | D021441 | — | — | 5 | 6 | — | — | 1 | 11 |
| T-cell lymphoma | D016399 | — | — | 5 | 7 | — | — | 1 | 10 |
| Myelodysplastic syndromes | D009190 | — | D46 | 6 | 4 | — | — | — | 10 |
Show 139 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Inflammation | D007249 | MP_0001845 | — | 1 | — | — | — | 4 | 5 |
| Neuroblastoma | D009447 | EFO_0000621 | — | 2 | — | — | — | 3 | 5 |
| Ureteral neoplasms | D014516 | EFO_0003844 | C66 | 4 | — | — | — | — | 4 |
| Pleural effusion | D010996 | — | J90 | 1 | — | — | — | 2 | 3 |
| Bone marrow diseases | D001855 | — | — | 1 | — | — | — | 1 | 2 |
| Pelvic neoplasms | D010386 | — | — | 2 | — | — | — | — | 2 |
| Chordoma | D002817 | EFO_0000334 | — | 1 | — | — | — | 1 | 2 |
| Acute disease | D000208 | — | — | 1 | — | — | — | 1 | 2 |
| Ascites | D001201 | — | R18 | 1 | — | — | — | 1 | 2 |
| Malignant pleural effusion | D016066 | — | J91.0 | 1 | — | — | — | 1 | 2 |
Show 30 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Spinal cord injuries | D013119 | EFO_1001919 | — | — | — | — | — | 10 | 10 |
| Traumatic brain injuries | D000070642 | — | S06 | — | — | — | — | 9 | 9 |
| Hernia | D006547 | — | K40-K46 | — | — | — | — | 8 | 8 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 8 | 8 |
| Brain injuries | D001930 | — | S06.9 | — | — | — | — | 8 | 8 |
| Osteoporosis | D010024 | EFO_0003882 | M81.0 | — | — | — | — | 7 | 7 |
| Inguinal hernia | D006552 | HP_0000023 | K40 | — | — | — | — | 4 | 4 |
| Intervertebral disc displacement | D007405 | EFO_1001800 | — | — | — | — | — | 4 | 4 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | — | 4 | 4 |
| Gestational diabetes | D016640 | — | O24.4 | — | — | — | — | 4 | 4 |
Show 202 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Deferiprone |
| INN | deferiprone |
| Description | Deferiprone is a member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia. It has a role as an iron chelator and a protective agent. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1c(O)c(=O)ccn1C |
Identifiers
| PDB | — |
| CAS-ID | 30652-11-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL70927 |
| ChEBI ID | 68554 |
| PubChem CID | 2972 |
| DrugBank | DB08826 |
| UNII ID | 2BTY8KH53L (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 297,329 documents
View more details
Safety
Black-box Warning
Black-box warning for: Deferiprone, Ferriprox
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
9,078 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use